Ready-to-use iPSC-based assay to screen ALS therapeutics

Background

Recent high-profile failures in Amyotrophic Lateral Sclerosis (ALS) drug clinical trials highlight a critical gap in the drug development process: the need for more reliable cell models to better predict clinical outcomes.

Would you like to get quick and reliable answers on the efficacy of your drug candidates targeting ALS?

Watch this on-demand webinar to explore our ready-to-use in vitro assay:

• Amenable for high-throughput formats
• Multiple disease-relevant readouts
• High robustness and reproducibility

Leveraging human iPSC technology, our assay gives you the edge in selecting drug candidates with a higher likelihood of late-stage success.

Learning Objectives

• Discover how iPSC technology can be integrated in your drug discovery pipeline for ALS
• Explore all the disease-relevant readouts available, assay formats and robustness
• Understand how a reliable assay can boost confidence in your research with a quick turnaround